IL-33/suppression of tumorigenicity 2 (ST2) signaling activates CD4+ Foxp3+ Tregs, promotes their accumulation in the colon, and accelerates AOM/DSS-induced colonic carcinogenesis, which may occur because blocking the IL-33/ST2 pathway reduces the IL-17 production by Foxp3+ Treg cells, thereby altering the inflammatory signaling in the TME and inhibiting Th17 differentiation. This evidence concerns the gene FOXP3 and infectious otitis media.